Explore insights by category
Drug Pipeline Insights Reports | Preparing for the GLP-1 Era | Regulatory updates | On-demand webinars | Podcasts | View all
Latest featured insights
E-book
Explore the dramatic changes in the years since 2000 — in drug performance and design, and especially affordability.
Article
Discover our latest innovation to the PA process — PreCheck Prior Authorization — which reduces approval times, appeals and denials.
Article
New biologics for breast cancer, hemophilia, and a rare form of heart disease are poised to add competition and choice in these classes.
Article
Biosimilars compete with expensive biologic drugs by offering the same safety and effectiveness, but at a lower cost.
Drug Pipeline Insights Reports
Report
Our report emphasizes new, next-gen and first-in-class treatments for cystic fibrosis, non-opioid treatment and GLP-1 drugs.
Article
New biologics for breast cancer, hemophilia, and a rare form of heart disease are poised to add competition and choice in these classes.
Report
A clever combination drug offers new help for schizophrenia with reduced side effects, while Dupixent expands its footprint to COPD.
Preparing for the GLP-1 Era
Article
After revolutionizing care for diabetes and weight loss, GLP-1 drugs are being eyed for more. Can we afford it?
Solution or product page
Get the most from these pricey new obesity drugs by choosing the right coverage strategy and helping your members build lifelong habits.
Regulatory updates
Article
In this conversation, learn the implications of new pharmacy legislation and rulemaking, and how you can manage your benefits effectively.
Article
An assessment of the latest rules impacting PBMs from state and federal legislation.
Solution or product page
Stay up-to-date on what’s happening in pharmacy legislation that has the potential to adversely impact pharmacy benefits offered by both fully insured and self-insured clients.
Latest on-demand webinars
On-demand webinar
From specialty pharmacy to drug affordability, our experts tackle your biggest pharmacy challenges.
Latest podcasts
Podcast
Listen to our resident experts discuss critical industry challenges and the solutions you need to control rising drug costs.
All pharmacy management insights (60)
Filter
Filtered by:
Filtered by:
-
New treatments for rare and common conditions
Our report emphasizes new, next-gen and first-in-class treatments for cystic fibrosis, non-opioid treatment and GLP-1 drugs.
-
A quarter-century of pharmacy benefit changes
Explore the dramatic changes in the years since 2000 — in drug performance and design, and especially affordability.
-
2024 in review
Another busy year in pharmacy is coming. Read about top stories in GLP-1s, biosimilars, top spend classes, key regulations and innovations.
-
Smart formulary management
Develop and manage formularies that bring clinical and financial value.
-
Automating the prior authorization process
Discover our latest innovation to the PA process — PreCheck Prior Authorization — which reduces approval times, appeals and denials.
-
The state of pharmacy regulations
In this conversation, learn the implications of new pharmacy legislation and rulemaking, and how you can manage your benefits effectively.
-
Key new drugs help close out 2024
New biologics for breast cancer, hemophilia, and a rare form of heart disease are poised to add competition and choice in these classes.
-
Biosimilars: Hard to make but lower costs
Biosimilars compete with expensive biologic drugs by offering the same safety and effectiveness, but at a lower cost.
-
Insights on GLP-1s: Costs and coverage
Balancing the risks and the benefits of GLP-1 drugs.
-
5 questions on health equity
Creating better health care access for all is a priority.
-
Aging workforce and the impact on drug spend
An estimated 23% of the workforce will be over age 65 by 2050 – but what does that mean for my drug plan?
-
Pharmacy legislative rules fall 2024
An assessment of the latest rules impacting PBMs from state and federal legislation.
-
New options to treat schizophrenia, COPD
A clever combination drug offers new help for schizophrenia with reduced side effects, while Dupixent expands its footprint to COPD.
-
Creating connections through partnership
Hear from an Optum Rx client on how we're partnering together for everyone we serve.
-
How to push back on 3 key pharmacy headwinds
Innovative formulary structures and clinical programs can help plan sponsors meet the challenge of expensive orphan, biologic and GLP-1 drugs.
-
Alzheimer's treatment: Time for a level-set?
See success rates, risks and costs of the new Alzheimer’s treatments.
-
Preparing your plan for the GLP-1 era
After revolutionizing care for diabetes and weight loss, GLP-1 drugs are being eyed for more. Can we afford it?
-
Taking the paper out of member communications
Discover how digital communications can increase member engagement and lower the cost of care.
-
The latest PBM regulations: Summer 2024
Get your guide to the evolving health care regulatory landscape and see what’s coming as lawmakers debate 600+ new bills impacting PBMs.
-
Specialty drugs: Not just set and forget?
For optimizing specialty drug therapy, monitoring patients throughout their care is key to cost-effective use of high-cost drugs.
-
Get immediate savings on specialty drugs
Specialty drug spend is a “top threat” to employer-provided benefits. Discover sustainable savings with your existing Optum Rx plan.
-
Building the PBM of the future
The solutions plan sponsors need today to tackle the pharmacy challenges of tomorrow.
-
Advanced Pharmacy Audit Services
See how a health plan used advanced audit services to prevent and detect pharmacy fraud, saving over $1 million.
-
How to eliminate prescription waste
Achieve savings by targeting expensive, low-value drugs.